Affiliation:
1. Division of Hematology and Oncology Department of Medicine Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA
Abstract
Despite the increased availability of tumor mutation testing and guideline‐based recommendations for managing newly diagnosed, advanced, or recurrent endometrial cancer, mortality in minority and underrepresented women continues to rise. Disparities in testing, referral to clinical genetics, and participation in clinical trials are persistent contributors to poor outcomes in this patient population.